Invivo Therapeutics Holdings Stock EBITDA
InVivo Therapeutics Holdings fundamentals help investors to digest information that contributes to InVivo Therapeutics' financial success or failures. It also enables traders to predict the movement of InVivo Stock. The fundamental analysis module provides a way to measure InVivo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to InVivo Therapeutics stock.
InVivo |
InVivo Therapeutics Holdings Company EBITDA Analysis
InVivo Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current InVivo Therapeutics EBITDA | (9.8 M) |
Most of InVivo Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InVivo Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, InVivo Therapeutics Holdings reported earnings before interest,tax, depreciation and amortization of (9.8 Million). This is 101.12% lower than that of the Health Care Equipment & Supplies sector and 109.79% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.25% higher than that of the company.
InVivo EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InVivo Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of InVivo Therapeutics could also be used in its relative valuation, which is a method of valuing InVivo Therapeutics by comparing valuation metrics of similar companies.InVivo Therapeutics is currently under evaluation in ebitda category among its peers.
InVivo Fundamentals
| Return On Equity | -0.98 | |||
| Return On Asset | -0.54 | |||
| Current Valuation | (7.59 M) | |||
| Shares Outstanding | 3.11 M | |||
| Shares Owned By Insiders | 0.02 % | |||
| Shares Owned By Institutions | 3.44 % | |||
| Number Of Shares Shorted | 17.63 K | |||
| Price To Earning | (1.90) X | |||
| Price To Book | 0.1 X | |||
| EBITDA | (9.8 M) | |||
| Net Income | (9.33 M) | |||
| Cash And Equivalents | 13.03 M | |||
| Cash Per Share | 9.36 X | |||
| Total Debt | 949 K | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 5.64 X | |||
| Book Value Per Share | 2.87 X | |||
| Cash Flow From Operations | (10.13 M) | |||
| Short Ratio | 0.91 X | |||
| Earnings Per Share | (3.28) X | |||
| Target Price | 37.5 | |||
| Beta | 0.66 | |||
| Market Capitalization | 995.92 K | |||
| Total Asset | 18.82 M | |||
| Retained Earnings | (248.62 M) | |||
| Working Capital | 15.13 M | |||
| Current Asset | 20.74 M | |||
| Current Liabilities | 3.31 M | |||
| Z Score | -18.62 | |||
| Net Asset | 18.82 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |